{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:55:52Z","timestamp":1787169352549,"version":"build-2736575974"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian Dermatol Online J"],"published-print":{"date-parts":[[2023]]},"DOI":"10.4103\/idoj.idoj_452_22","type":"journal-article","created":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T06:44:27Z","timestamp":1688107467000},"page":"465","source":"Crossref","is-referenced-by-count":38,"title":["Which is the ideal JAK inhibitor for alopecia areata \u2013 Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway"],"prefix":"10.4103","volume":"14","author":[{"given":"Kabir","family":"Sardana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savitha","family":"Bathula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananta","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2229-5178.379897-1","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/jid.2014.260","article-title":"Killing two birds with one stone: Oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis","author":"Craiglow","year":"2014","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/2229-5178.379897-2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.379897-3","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.15489","article-title":"JAK inhibitors for alopecia areata: A systematic review and meta-analysis","author":"Phan","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.379897-4","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.jisp.2017.10.003","article-title":"Tofacitinib for the treatment of severe alopecia areata in adults and adolescents","author":"Liu","year":"2018","journal-title":"J Investig Dermatol Symp Proc"},{"key":"key-10.4103\/2229-5178.379897-5","first-page":"311\u201328","article-title":"The JAK-STAT pathway: Impact on human disease and therapeutic intervention","author":"O'Shea","year":"2015","journal-title":"Annu Rev Med"},{"key":"key-10.4103\/2229-5178.379897-6","unstructured":"Sardana K. Tyrosine kinases and JAK inhibitors. In: Sardana K, editor. Systemic Drugs in Dermatology. 2nd ed. New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2022. p. 494-9."},{"key":"key-10.4103\/2229-5178.379897-7","doi-asserted-by":"crossref","first-page":"a028449","DOI":"10.1101\/cshperspect.a028449","article-title":"The common cytokine receptor \u03b3 chain family of cytokines","author":"Lin","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"key-10.4103\/2229-5178.379897-8","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1182\/blood-2008-09-181107","article-title":"Conditional deletion of STAT5 in adult mouse hematopoietic stem cells causes loss of quiescence and permits efficient nonablative stem cell replacement","author":"Wang","year":"2009","journal-title":"Blood"},{"key":"key-10.4103\/2229-5178.379897-9","first-page":"1174\u201381","article-title":"Inhibition of JAK-STAT signaling stimulates adult satellite cell function","author":"Price","year":"2014","journal-title":"Nat Med"},{"key":"key-10.4103\/2229-5178.379897-10","first-page":"1182\u20136","article-title":"STAT3 signaling controls satellite cell expansion and skeletal muscle repair","author":"Tierney","year":"2014","journal-title":"Nat Med"},{"key":"key-10.4103\/2229-5178.379897-11","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.bbadis.2013.05.030","article-title":"The role of JAK-STAT signaling in adipose tissue function","author":"Richard","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"key-10.4103\/2229-5178.379897-12","doi-asserted-by":"crossref","first-page":"e1500973","DOI":"10.1126\/sciadv.1500973","article-title":"Pharmacologic inhibition of JAK-STAT signaling promotes hair growth","author":"Harel","year":"2015","journal-title":"Sci Adv"},{"key":"key-10.4103\/2229-5178.379897-13","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata isdriven by cytotoxic T lymphocytes and is reversed by JAK inhibition","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"key-10.4103\/2229-5178.379897-14","first-page":"e121949","article-title":"High-throughput T cell receptor sequencing identifies clonally expanded CD81 T cell populations in alopecia areata","author":"de","year":"2018","journal-title":"JCI Insight"},{"key":"key-10.4103\/2229-5178.379897-15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/nature09114","article-title":"Genome-wide association study in alopecia areata implicates both innate and adaptive immunity","author":"Petukhova","year":"2010","journal-title":"Nature"},{"key":"key-10.4103\/2229-5178.379897-16","first-page":"729\u201338","article-title":"Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia: Possible mechanism via VEGF induction","author":"Meephansan","year":"2017","journal-title":"Arch Dermatol Res"},{"key":"key-10.4103\/2229-5178.379897-17","first-page":"947\u201357","article-title":"Transfer of CD8(+) cells induces localized hair loss whereas CD4(+)\/CD25(-) cells promote systemic alopecia areata and CD4(+)\/Cd25(+) cells blockade disease onset in the C3H\/HeJ mouse model","author":"McElwee","year":"2005","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/2229-5178.379897-18","first-page":"1335\u201351","article-title":"The role of lymphocytes in the development and treatment of alopecia areata","author":"Guo","year":"2015","journal-title":"Expert Rev Clin Immunol"},{"key":"key-10.4103\/2229-5178.379897-19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/jocd.12970","article-title":"The profile of cytokines (IL-2, IFN-gamma, IL-4, IL-10, IL-17A, and IL-23) in active alopecia areata","author":"Gautam","year":"2020","journal-title":"J Cosmet Dermatol"},{"key":"key-10.4103\/2229-5178.379897-20","first-page":"130","article-title":"Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity","author":"Bain","year":"2020","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.379897-21","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/15569527.2022.2084622","article-title":"Systematic review \u2013 Alopecia areata and tofacitinib in paediatric patients","author":"Bandeira","year":"2022","journal-title":"Cutan Ocul Toxicol"},{"key":"key-10.4103\/2229-5178.379897-22","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2229-5178.379897-23","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","article-title":"An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and universalis","author":"Jabbari","year":"2018","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/2229-5178.379897-24","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1111\/jocd.13966","article-title":"Experience with oral tofacitinib in severe alopecia areata with different clinical responses","author":"Dincer","year":"2021","journal-title":"J Cosmet Dermatol"},{"key":"key-10.4103\/2229-5178.379897-25","first-page":"978\u201380","article-title":"Oral tofacitinib monotherapy in Korean patients with refractory moderate-severe alopecia areata: A Case Series","author":"Park","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.379897-26","first-page":"503\u20138","article-title":"Brazilian experience of the treatment of alopecia universalis with the novel antirheumatic therapy tofacitinib: A case series","author":"Scheinberg","year":"2017","journal-title":"Rheumatol Ther"},{"key":"key-10.4103\/2229-5178.379897-27","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1111\/bjd.15483","article-title":"Image gallery: Treatment of refractory alopecia universalis with oral tofacitinib citrate and adjunct intralesional triamcinolone injections","author":"Strazzulla","year":"2017","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.379897-28","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2147\/CCID.S309215","article-title":"A comprehensive literature review of JAK inhibitors in treatment of alopecia areata","author":"Dillon","year":"2021","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"key-10.4103\/2229-5178.379897-29","first-page":"41\u20136","article-title":"Comparison of the treatment outcome of oral tofacitinib with other conventional therapies in refractory alopecia totalis and universalis: A retrospective study","author":"Shin","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"key-10.4103\/2229-5178.379897-30","first-page":"e89776","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","author":"Kennedy","year":"2016","journal-title":"JCI Insight"},{"key":"key-10.4103\/2229-5178.379897-31","doi-asserted-by":"crossref","first-page":"891434","DOI":"10.3389\/fmed.2022.891434","article-title":"Oral Tofacitinib and systemic corticosteroids, alone or in combination, in patients with moderate-to-severe alopecia areata: A retrospective study","author":"Zhang","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"key-10.4103\/2229-5178.379897-32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1159\/000494613","article-title":"Janus kinase inhibitors for the treatment of severe alopecia areata: An open-label comparative study","author":"Almutairi","year":"2019","journal-title":"Dermatology"},{"key":"key-10.4103\/2229-5178.379897-33","unstructured":"XELJANJ (tofacitinib) [package insert]. Manhattan (NY): Pfizer Corporation; 2012. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/203214s028,208246s013,213082s003lbl.pdf. [Last accessed on 2022 Oct 21]."},{"key":"key-10.4103\/2229-5178.379897-34","first-page":"89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"key-10.4103\/2229-5178.379897-35","first-page":"412\u20139","article-title":"Ruxolitinib cream for the treatment of patients with alopecia areata: A 2-part, double-blind, randomized, vehicle-controlled Phase 2 study","author":"Olsen","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.379897-36","unstructured":"JAKAFI\u00ae (ruxolitinib) [package insert]. Wilmington (DE): Incyte Corporation; 2011. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/202192Orig1s019Rpllbl.pdf. [Last accessed on 2022 Oct 21]."},{"key":"key-10.4103\/2229-5178.379897-37","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","author":"King","year":"2022","journal-title":"N Engl J Med"},{"key":"key-10.4103\/2229-5178.379897-38","unstructured":"OLUMIANT (baricitinib) [package insert]. LLC Indianapolis (USA): YYYY, Eli Lilly and Company; 2018. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/203214s028,208246s013,213082s003lbl.pdf. [Last accessed on 2022 Oct 21]."},{"key":"key-10.4103\/2229-5178.379897-39","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.jaad.2022.03.045","article-title":"Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata","author":"King","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.379897-40","doi-asserted-by":"crossref","first-page":"e142205","DOI":"10.1172\/jci.insight.142205","article-title":"Selective inhibition of JAK3 signaling is sufficient to reverse alopecia areata","author":"Dai","year":"2021","journal-title":"JCI Insight"},{"key":"key-10.4103\/2229-5178.379897-41","doi-asserted-by":"crossref","first-page":"e0164080","DOI":"10.1371\/journal.pone.0164080","article-title":"JAK3 as an emerging target for topical treatment of inflammatory skin diseases","author":"Alves","year":"2016","journal-title":"PLoS One"},{"key":"key-10.4103\/2229-5178.379897-42","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","article-title":"Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers","author":"Guttman-Yassky","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"key-10.4103\/2229-5178.379897-43","unstructured":"FDA and EMA accept regulatory submission for Pfizer's ritlecitinib for individuals 12 years and older with alopecia areata. News release. September 9, 2022. Available from: https:\/\/www.businesswire.com\/news\/home\/20220908006121\/en\/FDA-and EMA-Accept-Regulatory-Submission-for-Pfizer%E2%80%99s-Ritlecitinib-for-Individuals-12-Years-and-Older-with-Alopecia-Areata. [Last accessed on 2022 Oct 21]."},{"key":"key-10.4103\/2229-5178.379897-44","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/jdv.17909","article-title":"Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib","author":"Winnette","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.379897-45","first-page":"542\u201350","article-title":"JAK and STAT signaling molecules in immunoregulation and immune-mediated disease","author":"O'Shea","year":"2012","journal-title":"Immunity"},{"key":"key-10.4103\/2229-5178.379897-46","doi-asserted-by":"crossref","first-page":"955038","DOI":"10.3389\/fimmu.2022.955038","article-title":"Induction of T cell exhaustion by JAK1\/3 inhibition in the treatment of alopecia areata","author":"Dai","year":"2022","journal-title":"Front Immunol"},{"key":"key-10.4103\/2229-5178.379897-47","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3389\/fimmu.2018.01347","article-title":"Metabolic reprogramming and longevity of tissue-resident memory T cells","author":"Pan","year":"2018","journal-title":"Front Immunol"},{"key":"key-10.4103\/2229-5178.379897-48","first-page":"486\u201399","article-title":"Molecular and cellular insights into T cell exhaustion","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"key-10.4103\/2229-5178.379897-49","first-page":"1911\u201366","article-title":"Montagna symposium 2017- Janus kinase inhibitors for treatment of alopecia areata","author":"Wang","year":"2018","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/2229-5178.379897-50","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1111\/jocd.14726","article-title":"Pertinent role of maintenance dose of oral tofacitinib in a child with alopecia totalis with a 2.5-year follow-up on low dose","author":"Sardana","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"key-10.4103\/2229-5178.379897-51","doi-asserted-by":"crossref","first-page":"5370","DOI":"10.1111\/jocd.15108","article-title":"Update on pharmacology, actions, dosimetry and regimens of oral glucocorticoids in dermatology","author":"Sardana","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"key-10.4103\/2229-5178.379897-52","doi-asserted-by":"crossref","unstructured":"Virtanen A, Palmroth M, Liukkonen S, Kurttila A, Haikarainen T, Isom\u00e4ki P, Silvennoinen O. In vitro profiling of rheumatic-disease-evaluated JAK inhibitors demonstrate differences in JAK isoform selectivity between different types of inhibitors. Arthritis Rheumatol 2023. doi: 10.1002\/art.42547.","DOI":"10.1002\/art.42547"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:51:25Z","timestamp":1787165485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/idoj.idoj_452_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"alternative-id":["379897"],"URL":"https:\/\/doi.org\/10.4103\/idoj.idoj_452_22","relation":{},"ISSN":["2229-5178"],"issn-type":[{"value":"2229-5178","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]}}}